Exelixis, Inc. (NASDAQ:EXEL) Shares Sold by Blair William & Co. IL

Blair William & Co. IL lowered its holdings in Exelixis, Inc. (NASDAQ:EXEL) by 39.7% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 457,570 shares of the biotechnology company’s stock after selling 300,760 shares during the period. Blair William & Co. IL owned about 0.16% of Exelixis worth $15,237,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also made changes to their positions in the company. Principal Securities Inc. grew its position in Exelixis by 62.8% in the fourth quarter. Principal Securities Inc. now owns 967 shares of the biotechnology company’s stock worth $32,000 after buying an additional 373 shares during the last quarter. USA Financial Formulas acquired a new stake in shares of Exelixis during the fourth quarter worth $32,000. Kestra Investment Management LLC purchased a new stake in shares of Exelixis during the fourth quarter valued at $39,000. UMB Bank n.a. boosted its position in shares of Exelixis by 68.4% in the 4th quarter. UMB Bank n.a. now owns 1,361 shares of the biotechnology company’s stock valued at $45,000 after purchasing an additional 553 shares during the period. Finally, Crowley Wealth Management Inc. purchased a new position in Exelixis in the 4th quarter worth about $50,000. 85.27% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

Several research analysts have commented on EXEL shares. JMP Securities reiterated a “market outperform” rating and issued a $41.00 target price on shares of Exelixis in a report on Thursday, January 23rd. Oppenheimer cut shares of Exelixis from an “outperform” rating to a “market perform” rating and lowered their price objective for the stock from $41.00 to $33.00 in a research report on Friday, January 24th. Stifel Nicolaus increased their target price on Exelixis from $30.00 to $36.00 and gave the company a “hold” rating in a report on Wednesday, February 12th. StockNews.com upgraded Exelixis from a “buy” rating to a “strong-buy” rating in a report on Wednesday, February 19th. Finally, Wells Fargo & Company downgraded Exelixis from an “overweight” rating to an “equal weight” rating and set a $36.00 price objective for the company. in a research note on Monday, February 24th. One analyst has rated the stock with a sell rating, eight have issued a hold rating, eleven have issued a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat.com, Exelixis currently has a consensus rating of “Moderate Buy” and a consensus price target of $37.59.

Exelixis Trading Down 0.4 %

EXEL stock opened at $36.70 on Friday. The firm has a market cap of $10.27 billion, a PE ratio of 20.73, a PEG ratio of 1.13 and a beta of 0.57. Exelixis, Inc. has a 1 year low of $20.14 and a 1 year high of $40.02. The company has a fifty day simple moving average of $35.71 and a 200 day simple moving average of $33.22.

Exelixis (NASDAQ:EXEL) last announced its quarterly earnings results on Tuesday, February 11th. The biotechnology company reported $0.48 earnings per share for the quarter, missing analysts’ consensus estimates of $0.51 by ($0.03). Exelixis had a return on equity of 23.52% and a net margin of 24.04%. As a group, analysts forecast that Exelixis, Inc. will post 2.04 EPS for the current fiscal year.

Insiders Place Their Bets

In other Exelixis news, EVP Patrick J. Haley sold 10,000 shares of the company’s stock in a transaction dated Monday, March 3rd. The shares were sold at an average price of $38.80, for a total transaction of $388,000.00. Following the completion of the sale, the executive vice president now directly owns 341,028 shares in the company, valued at $13,231,886.40. This represents a 2.85 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Mary C. Beckerle sold 12,210 shares of Exelixis stock in a transaction dated Friday, February 14th. The stock was sold at an average price of $34.88, for a total value of $425,884.80. Following the completion of the transaction, the director now owns 30,406 shares in the company, valued at $1,060,561.28. The trade was a 28.65 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 140,343 shares of company stock valued at $5,177,234 over the last 90 days. 2.85% of the stock is currently owned by company insiders.

Exelixis Profile

Exelixis, Inc, an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer.